{
  "slug": "grey-market-glp1",
  "round": 2,
  "date": "2026-10-14",
  "authoring_model": "Sol 6.1",
  "reviewer": "Claude Opus 5.5 (Anthropic)",
  "canonical_path": "consensus_consistency_audit_2026-10-09/revised/grey-market-glp1/grey-market-glp1.review.md",
  "edition": "revised edition carrying the Consensus consistency validation section of 2026-10-09",
  "level_before": "Α",
  "level_after": "Α",
  "confidence_before": "Moderate",
  "confidence_after": "Moderate",
  "role_before": "epiphenomenon",
  "role_after": "epiphenomenon",
  "msd_before": {"momentum": "Mechanistic only", "stability": "Stable", "divergence": "Contested"},
  "msd_after": {"momentum": "Mechanistic only", "stability": "Stable", "divergence": "Contested"},
  "counts": {"critical": 0, "major": 2, "minor": 3, "editorial": 0, "total": 5},
  "revision_regressions": ["E1", "E5"],
  "pmids_checked": 57,
  "pmids_in_references": 51,
  "pmids_failed": 0,
  "claims_spot_checked": 13,
  "claims_misattributed": 0,
  "validator": "PASS - 0 fail, 0 warn, 30 pass (v5 validator matching the review's declared HSEF v5.3; the package's own 5.4 validator reports 1 FAIL for a missing v5.4 lay_summary, a validator-version mismatch)",
  "findings": [
    {
      "id": "E1",
      "severity": "Major",
      "regression": true,
      "type": "internal consistency (revision regression)",
      "location": "REVIEWER NOTES",
      "original": "No independent blind grading, Consensus, Scite or independent scientific peer review was performed.",
      "corrected": "No independent blind grading, Scite or independent scientific peer review was performed, and no Consensus work informed the original grading; the dated Consensus consistency validation section above was added on 9 October 2026 as source reconciliation only and changed no grade or count.",
      "evidence": "The 9 October revision spliced in a section documenting a named Consensus Pro thread, a provider artifact set and a four-source primary-record reconciliation, while leaving the preserved reviewer note asserting that no Consensus work was performed. Defect introduced by the revision, not inherited. Repaired by scoping the original sentence so both blocks remain true and neither is deleted."
    },
    {
      "id": "E2",
      "severity": "Minor",
      "type": "citation integrity",
      "location": "Consensus consistency validation, primary-source reconciliation",
      "original": "PMID not resolved in its own metadata; DOI 10.1001/jamanetworkopen.2024.28280",
      "corrected": "carried no PMID in its own metadata; it resolves in PubMed as PMID 39093567; DOI 10.1001/jamanetworkopen.2024.28280",
      "evidence": "The record resolves: Ashraf AR, Mackey TK, Schmidt J et al., 'Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases', JAMA Network Open 2024;7(8):e2428280. The original wording was literally about the provider's metadata but reads as though no PubMed record exists. The judgement that it is the same test-purchase evidence family and adds no independent study count is correct and unchanged."
    },
    {
      "id": "E3",
      "severity": "Minor",
      "type": "scoring logic (required artifact)",
      "location": "Final score, causal direction and M/S/D; scorecard extended_scoring_MSD.divergence",
      "original": "Divergence: Contested; no single implied-level arithmetic.",
      "corrected": "Divergence rationale now names the split between supplier and user-forum framing and the regulatory, analytical and pharmacovigilance literature; value unchanged.",
      "evidence": "Framework requires a checkable artifact for Divergence."
    },
    {
      "id": "E4",
      "severity": "Minor",
      "type": "rendering defect",
      "location": "Evidence cards, 3 sites",
      "original": "ErratumIn: PMID38913535",
      "corrected": "Erratum in: PMID 38913535",
      "evidence": "Known builder defect; all three errata verified as Published Errata attached to the correct parent rows."
    },
    {
      "id": "E5",
      "severity": "Major",
      "regression": true,
      "type": "false presupposition (revision regression)",
      "location": "Consensus consistency validation, closing paragraph; consensus-addendum.md",
      "original": "Its original narrative, registered scope, source inventory, grades and any earlier approval remain historical records; the earlier approval does not certify this supplement.",
      "corrected": "Its original narrative, registered scope, source inventory and grades remain historical records. No adversarial approval was attached to this case before 14 October 2026, so this supplement neither carries nor extends one.",
      "evidence": "The second clause presupposed an earlier adversarial approval. None exists: the earlier edition under hsef_v53_remaining_priority_01_05_2026-10-09 carries no approval section and that package holds no adversarial-review artifacts. Spliced in unconditionally by the 9 October revision, so a defect the revision introduced. Rescoped rather than deleted, identically in both files."
    }
  ],
  "rejected_findings": [
    "Alpha for SC3 and the headline, checked in both directions: the review neither says grey-market products are inert or uniformly dangerous nor overstates the evidence, and no examined source provides a controlled clinical equivalence comparison.",
    "SC2 at Beta: direct product assays are measurements, so cap 2 is the correct binding rule.",
    "Causal role 'epiphenomenon' at derivation step 2: awkward on a supply-chain claim but the derivation is written out and labelled operational rather than a finding of inertness.",
    "Momentum 'Mechanistic only' and Stability 'Stable': both carry the required artifact and name the records they rest on.",
    "The endotoxin upper-bound qualification: verified against the source Results; it narrows how two numbers may be quoted without narrowing the finding that endotoxin was present in every delivered vial.",
    "Poison-centre calls and spontaneous reports treated as signals rather than incidence; absence of a denominator is not converted into absence of harm.",
    "Supplemental status of PMID 42137313 and 42533250: correctly excluded from the frozen 51-source count.",
    "Citation years differing by one year; PubMed titles dropping Greek letters; no collective-author rendering defect; review_metadata.reviewer 'Codex' left alone as house provenance.",
    "'Best-supported rival' checked for the models_evaluated[0] renderer defect: here that entry is the rank-1 non-nominal model and the nominal sits at rank 3, so the prose is correct.",
    "Confidence Moderate verified against the framework's confidence text rather than access depth: High requires extensive independent replication across labs, models and assay modalities, and the supply-side evidence is a handful of test purchases and voluntary reports."
  ],
  "residual_limitations": "One of 51 sources examined beyond abstract depth. Everything known about product quality in this market comes from a handful of test purchases and from voluntary reports with no exposed-user denominator, so neither the hazards nor their rarity is quantified. The review assesses equivalence of efficacy only; it is not a safety assessment of grey-market GLP-1 use and contains no sourcing, dosing or self-administration guidance.",
  "propagation": {
    "propagate_to": [],
    "divergent_copies": ["hsef_v53_remaining_priority_01_05_2026-10-09/grey-market-glp1/grey-market-glp1.review.md"],
    "divergent_copies_note": "Not overwritten. The earlier edition (737 lines vs 764) lacks the spliced Consensus consistency validation section and therefore does not carry the E1 or E5 regressions; it also carries none of this pass's corrections."
  },
  "approval": "Approved as revised. — Claude Opus 5.5 (Anthropic), 2026-10-14."
}